Bailard Inc. Sells 130,000 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Bailard Inc. reduced its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 41.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 180,200 shares of the company’s stock after selling 130,000 shares during the period. Bailard Inc.’s holdings in Teva Pharmaceutical Industries were worth $3,020,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. New Age Alpha Advisors LLC purchased a new position in shares of Teva Pharmaceutical Industries during the 1st quarter worth approximately $43,000. Sound Income Strategies LLC boosted its position in shares of Teva Pharmaceutical Industries by 3,715.8% during the second quarter. Sound Income Strategies LLC now owns 2,900 shares of the company’s stock valued at $49,000 after purchasing an additional 2,824 shares in the last quarter. Banque Cantonale Vaudoise bought a new stake in shares of Teva Pharmaceutical Industries during the first quarter valued at approximately $74,000. Brooklyn Investment Group grew its stake in Teva Pharmaceutical Industries by 403.4% in the first quarter. Brooklyn Investment Group now owns 5,009 shares of the company’s stock worth $77,000 after purchasing an additional 4,014 shares during the period. Finally, CWM LLC raised its holdings in Teva Pharmaceutical Industries by 18.1% in the second quarter. CWM LLC now owns 4,995 shares of the company’s stock worth $84,000 after purchasing an additional 767 shares in the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 200,000 shares of the company’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $24.11, for a total transaction of $4,822,000.00. Following the transaction, the director directly owned 495,000 shares of the company’s stock, valued at $11,934,450. This represents a 28.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.55% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Stock Up 2.6%

NYSE:TEVA opened at $25.78 on Thursday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06. The firm has a market cap of $29.56 billion, a P/E ratio of -161.10, a P/E/G ratio of 1.11 and a beta of 0.70. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $25.88. The firm has a 50-day simple moving average of $20.12 and a two-hundred day simple moving average of $18.08.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.68 by $0.10. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The firm had revenue of $4.48 billion for the quarter, compared to analysts’ expectations of $4.36 billion. During the same quarter in the prior year, the company posted $0.69 earnings per share. The business’s revenue for the quarter was up 3.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.550-2.650 EPS. Analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

TEVA has been the topic of a number of research reports. UBS Group boosted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the company an “overweight” rating in a report on Thursday, November 6th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $25.86.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.